Part the Cloud: Phase 1 and Phase 2 Clinical Studies — 2027 Funding
Neuroscience, Biology and Medicine research grant from Alzheimer’s Association
About
Supports translational studies of potential Alzheimer’s and related-dementia therapies, including early human safety, target engagement and proof of mechanism. Awards provide up to USD 1 million over two to three years; selected Phase 3 or biomarker-validation proposals can also qualify. Letters of intent are due 20 October 2026 at 17:00 Eastern time (22 October for ISTAART members); invited full applications follow on 15 December (17 December for members).
Eligibility
Career stage: Early independent researcher · Mid-career researcher · Established researcher
Institution applies
Covers: Up to USD 1 million total over two to three years.
Host location: Worldwide
International applicants, including eligible institutions in Austria and Europe; organisation and sanctions exclusions apply.
Reviewed Sep 24, 2026. Check the funder’s full conditions before applying.
Full-time investigators at Assistant Professor level or equivalent and above; students and postdocs cannot be lead applicants. Eligible international institutions may apply, subject to programme and sanctions rules. Only one proposal per applicant across the current competition; reporting and institutional exclusions apply.
Topics
Related funding
Part the Cloud: Combination Therapies Program — 2027 Funding
Supports Phase 1–3 trials of combination approaches for Alzheimer’s disease and related dementias, with mechanistic rationale and appropriate biomarkers. Phase 1 support is capped at USD 1 million…
Part the Cloud: Enable the Molecule for AI-Discovered Programs — 2027 Funding
Funds experimental advancement of AI-discovered therapeutic leads for Alzheimer’s disease and related dementias. Separate tracks support lead optimization and work enabling an…
Clinical Research
Funding for non-commercial clinical research that can improve clinical practice, diagnosis or treatment. Eligible neuroscience and neurological research must meet the clinical programme requirements.
Source: alz.org